Article
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.
JAMA - 11 May 2005
Hakonarson Hakon, Thorvaldsson Sverrir, Helgadottir Anna, Gudbjartsson Daniel, Zink Florian, Andresdottir Margret, Manolescu Andrei, Arnar David O, Andersen Karl, Sigurdsson Axel, Thorgeirsson Gestur, Jonsson Asgeir, Agnarsson Uggi, Bjornsdottir Halldora, Gottskalksson Gizur, Einarsson Atli, Gudmundsdottir Hrefna, Adalsteinsdottir Asdis E, Gudmundsson Kolbeinn, Kristjansson Kristleifur, Hardarson Thordur, Kristinsson Arni, Topol Eric J, Gulcher Jeffrey, Kong Augustine, Gurney Mark, Thorgeirsson Gudmundur, Stefansson Kari
Abstract excerpt
CONTEXT: Myocardial infarction (MI) is the leading cause of death in the world. Variants in the 5-lipoxygenase-activating protein (FLAP) gene are associated with risk of MI. OBJECTIVE: To determine the effect of an inhibitor of FLAP on levels of biomarkers associated with MI risk. DESIGN, SETTING, AND PATIENTS: A randomized, prospective, placebo-controlled, crossover trial of an inhibitor of FLAP (DG-031) in MI...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
